Datensatz

Sos,  Martin L.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Dietlein,  Felix
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Peifer,  Martin
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Schöttle,  Jakob
Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Balke-Want,  Hyatt
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Müller,  Christian
Max Planck Society;

Koker,  Mirjam
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Richters,  André
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Heynck,  Stefanie
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Malchers,  Florian
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Heuckmann,  Johannes M.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Seidel,  Danila
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Eyers,  Patrick A.
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Ullrich,  Roland T.
Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;

Antonchik,  Andrey P.
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Vintonyak,  Viktor V.
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Schneider,  Peter M.
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Ninomiya,  Takashi
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Waldmann,  Herbert H.
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Büttner,  Reinhard
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Rauh,  Daniel
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Heukamp,  Lukas
a Department of Translational Genomics, University of Cologne, 50931 Cologne, Germany b Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, United States c Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, United States d Chemical Genomics Center, Max Planck Society, 44227 Dortmund, Germany e Technical University Dortmund, D-44221 Dortmund, Germany f Cancer Research United Kingdom (CR-UK), Department of Oncology, University of Sheffield, Sheffield S10 2RX, United Kingdom g Max Planck Institute of Molecular Physiology, D-44227 Dortmund, Germany h Institute of Forensic Medicine, University of Cologne, 50823 Cologne, Germany i Department of Hematology, Oncology, and Respiratory Medicine, Okayama University, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 700-8558 Okayama, Japan j Institute of Pathology, University of Cologne, 50924 Cologne, Germany;

Thomas,  Roman K.
Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society;